Global /United States /Healthcare /Biotechnology /NUVB

Nuvation Bio Inc.

NUVB

• NYSE: NUVB • Delayed

4.34USD -4.8%

As of 13 June 2026, Nuvation Bio Inc. has a market cap of $1.51B USD, ranking #8423 globally and #1887 in the United States. It ranks #707 in the Healthcare sector, and #137 in the Biotechnology industry.

Global Rank

8423

Country Rank

1887

Sector Rank

707

Industry Rank

137

Key Stats

Market Cap

$1.51BUSD

Enterprise Value

$1.02BUSD

Revenue (TTM)

$62.9MUSD

EBITDA (TTM)

-$211.33MUSD

Net Income (TTM)

-$204.63MUSD

PS Ratio

23.5

PB Ratio

5.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

David Hung open_in_new

Employees

298

Founded

2018

Website

nuvationbio.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.8%	-15%	2.1%	-18%	-19%	-52%	101%	170%	-62%

News

NUVB Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE MIC: XNYS PRIMARY	NUVB Nuvation Bio Inc Ordinary Shares - Class A ISIN: US67080N1019 Shares Out.: Shares Outstanding: 348.202M¹ Shares Float: 253.662M² TV: TradingView: NYSE: NUVB SA: Stock Analysis: NYSE: NUVB YF: Yahoo Finance: NUVB GF: Google Finance: NYSE: NUVB NQ: NASDAQ: NUVB BA: Barron's: NUVB MS: Morningstar: XNYS: NUVB	4.34 USD	TV: TradingView: NYSE: NUVB SA: Stock Analysis: NYSE: NUVB YF: Yahoo Finance: NUVB GF: Google Finance: NYSE: NUVB NQ: NASDAQ: NUVB BA: Barron's: NUVB MS: Morningstar: XNYS: NUVB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 12K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 10K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 2K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 2K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 2K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 1K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 3K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 3K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 3K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 3K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 2K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 2K%	-	Germany

chevron_leftBack